Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Baader Bank Aktiengesellschaft

Key Points

• Baader Bank Aktiengesellschaft increased its stake in Novo Nordisk A/S by 224.4% in the first quarter, owning 13,224 shares valued at $918,000.
• Novo Nordisk A/S reported a revenue of $11.87 billion for the quarter, with an EPS of $0.92 that met analysts' expectations.
• Institutional investors now hold 11.54% of Novo Nordisk A/S stock, with notable increases in holdings from firms like Wellington Management Group and Nomura Asset Management.

Baader Bank Aktiengesellschaft raised its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 224.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,224 shares of the company's stock after purchasing an additional 9,148 shares during the quarter. Baader Bank Aktiengesellschaft's holdings in Novo Nordisk A/S were worth $918,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after buying an additional 200 shares during the period. Nomura Asset Management Co. Ltd. raised its holdings in shares of Novo Nordisk A/S by 113.1% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 43,776 shares of the company's stock valued at $3,766,000 after buying an additional 23,238 shares during the period. Wellington Management Group LLP raised its holdings in shares of Novo Nordisk A/S by 135.3% in the 4th quarter. Wellington Management Group LLP now owns 830,435 shares of the company's stock valued at $71,434,000 after buying an additional 477,557 shares during the period. Summit Financial LLC raised its holdings in shares of Novo Nordisk A/S by 122.1% in the 4th quarter. Summit Financial LLC now owns 10,617 shares of the company's stock valued at $913,000 after buying an additional 5,837 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $893,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on NVO. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a report on Thursday. Hsbc Global Res downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday. Finally, BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $93.67.

Novo Nordisk A/S Stock Up 2.5%

NVO traded up $1.16 on Friday, hitting $48.23. 34,710,384 shares of the company were exchanged, compared to its average volume of 17,615,270. Novo Nordisk A/S has a twelve month low of $46.90 and a twelve month high of $139.74. The company has a market cap of $215.35 billion, a price-to-earnings ratio of 14.27, a price-to-earnings-growth ratio of 1.41 and a beta of 0.63. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $69.26 and a two-hundred day moving average price of $72.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion during the quarter. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.